Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase-naïve and pre-treated patients, and is expected to enter a registrational study in the second half of 2019. Turning Point’s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to overcome treatment resistance common in other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. For more information, visit www.tptherapeutics.com.
Employees: 201-500
Total raised: $327.5M
Founded date: 2013
Investors 7
| Date | Name | Website |
| - | SV Tech Ve... | svtechvent... |
| - | Foresite C... | foresiteca... |
| - | ChinaRock ... | crcmventur... |
| - | Harbinger ... | harbingerv... |
| - | OrbiMed | orbimed.co... |
| - | HBM Partne... | hbmpartner... |
| - | SR One | srone.com |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 17.09.2019 | - | $202.5M | - |
| 24.10.2018 | - | $80M | Foresite C... |
| 23.05.2017 | Series C | $45M | OrbiMed |
Mentions in press and media 17
| Date | Title | Description | Source |
| 13.06.2022 | Bristol Myers Squibb Buys Turning Point | Bristol Myers Squibb (BMS) is further strengthening its ties to San Diego. On June 3, the New York-... | sdbj.com/n... |
| 07.06.2022 | How air taxi unicorn Volocopter plans to fund its 2024 servi... | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign ... | fortune.co... |
| 06.06.2022 | Why the fates of PE and VC-backed companies may diverge in 2... | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign ... | fortune.co... |
| 13.04.2022 | Turning Point looks to challenge Pfizer, Roche with new e... | Turning Point Therapeutics shared a Phase I/II update for its lead drug candidate repotrect... | endpts.com... |
| 11.11.2021 | Jubilant Biosys Limited Announces New Chemistry Innovation R... | SAN DIEGO and BENGALURU, India, Nov. 11, 2021 /PRNewswire/ -- Jubilant Biosys Limited announced toda... | en.prnasia... |
| 11.09.2019 | Turning Point Therapeutics Raises $202.5M in Follow-On Offer... | After raising $175.2 million in an initial public offering this spring, Turning Point Therapeutics h... | sdbj.com/n... |
| 14.04.2019 | Turning Point Therapeutics Lays Out Terms for $125M IPO | Turning Point Therapeutics — which is developing drugs for treatment-resistant cancers — set terms f... | sdbj.com/n... |
| 19.10.2018 | TP Therapeutics Completes $80M Mezzanine Financing | TP Therapeutics, a San Diego, CA-based clinical-stage precision oncology company developing novel dr... | finsmes.co... |
| 19.10.2018 | TP Therapeutics raises $80M as CMO Countouriotis takes the h... | TP Therapeutics has netted $80 million and a new CEO as it looks to move its lead candidate targetin... | fiercebiot... |
| 19.10.2018 | TP Therapeutics raises $80M as CMO Countouriotis takes the h... | TP Therapeutics has netted $80 million and a new CEO as it looks to move its lead candidate targetin... | fiercebiot... |
Show more